[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580525":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":15,"collaborators":17,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":10},{"fullName":5,"class":6},"Shanghai Gynecologic Oncology Group","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with newly diagnosed advanced epithelial ovarian cancer",null,"Patients who were newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer between December 2013 and December 2024.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients with platinum-sensitive first relapsed epithelial ovarian cancer","Patients with platinum-sensitive first relapsed ovarian cancer who were diagnosed between December 2013 and December 2024",{"type":16,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[18,21,23,25],{"name":19,"class":20},"Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China","UNKNOWN",{"name":22,"class":20},"Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China",{"name":24,"class":20},"Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University",{"name":26,"class":20},"Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China","100580525","parpi-and-ovarian-cancer-survival-100580525",false,"NCT06838429","PARPi and Ovarian Cancer Survival","Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study","Inclusion Criteria:\n\nGroup 1:\n\n* Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.\n* Complete data on first-line treatment and maintenance therapy.\n* Availability of follow-up data.\n\nGroup 2:\n\n* Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.\n* Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.\n* Complete data on second-line treatment and maintenance therapy.\n* Availability of follow-up data.\n\nExclusion Criteria:\n\nGroup 1:\n\n* Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.\n* Missing first-line or follow-up data.\n\nGroup 2:\n\n* Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.\n* Patients with second relapse.\n* Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.\n* Missing second-line or follow-up data.","FEMALE","18 Years","80 Years",{"count":38,"type":39},6000,"ESTIMATED","OBSERVATIONAL","With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.",[43,44],"Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum","PARP Inhibitor","NOT_YET_RECRUITING","2025-02-17",{"date":48,"type":49},"2025-02-20","ACTUAL",{"date":51,"type":39},"2025-03",{"date":53,"type":39},"2026-03",{"name":5,"class":6}]